Compare
Compare archived captures
This view highlights text differences between two archived captures. It does not interpret meaning or provide guidance.
Descriptive changes only
This comparison highlights text changes between archived captures. It does not interpret the change or provide medical advice. For up-to-date recommendations, always consult the official source website.
Need to cite this comparison? See /cite.
Earlier capture
Notice of Compliance - Drug Products - Canada.ca
Apr 18, 2025
legacy-hc-2025-04-21
ID 141329
Later capture
Notice of Compliance - Drug Products - Canada.ca
Jan 1, 2026
hc-20260101
ID 404959
updated1 sections changed
1 sections changed0 added0 removed+0 / -1 linesChange ratio: 1%
--- +++ @@ -47,5 +47,4 @@ outlines another option for manufacturers wishing to receive authorization through an NOC to market brand name and generic drug products. This policy applies to eligible drug submissions submitted to Health Canada for a change in the manufacturer's name and/or product name subsequent to a merger, buy-out or other corporate restructuring or the establishment of a licensing agreement. Products that receive an NOC according to one of these mechanisms have met Health Canada's regulatory requirements for safety, efficacy and quality. Page details-Date modified: 2018-02-28